The Darwin Prospective Melioidosis Study: Years 27-31
Funder
National Health and Medical Research Council
Funding Amount
$1,281,718.00
Summary
The Darwin Prospective Melioidosis Study has documented 914 cases since 1989, with 115 fatalities. A surge in Darwin melioidosis cases over the past 5 years has been linked to urban development and the discovery of a new bacterial strain. Whole genome sequencing of our unique 25+ year set of bacteria and their linked patient data will unravel the changing epidemiology and identify important virulence factors, forming a foundation for future diagnostics, therapeutics, and vaccines.
Group A streptococcus (GAS) is a bacteria that causes a wide range of disease in humans. GAS diseases are more common in Australias Indigenous population, and other health and economically disadvantaged groups than more affluent groups. In this study we will evaluate the effectiveness of novel vaccine candidates designed to prevent infection from all strains of GAS.